The IHC-based detection of CD73 employed an antibody that did not compete with the murine surrogate antibody of Oleclumab; therefore, the lower levels of CD73 protein were consistent with Oleclumab’s known ability to internalize CD73.7 IMC highlighted that CT26 tumors from aCD73 treated mice tended to have lower frequencies of cells expressing markers known to associate with suppressive tumor associated macrophages (Figure 3d shaded panel) and with cancer associated fibroblasts (Figure 3d). This evidence concerns the gene DDX53 and neoplasm.